Decitabine regulates the resistance of HCC to sorafenib through demethylation

Abstract Purpose To evaluate the efficacy of sorafenib in combination with the DNA methylation inhibitor decitabine (DAC) for the treatment of hepatocellular carcinoma (HCC), and to investigate the mechanism of sorafenib resistance from an epigenetic perspective, aiming to provide new insights and s...

詳細記述

書誌詳細

出版年:	Clinical Epigenetics
主要な著者:	Miao Zhang, Xiaolei Zhou, Zhenzhen Li, TianYu Zhao, Yu Miao, Sen Liu, Qiaoqiao Han, Libo Wang, Yongdeng Xu, Tao Cui, Ze Wang, Xiulin Yi, Fengying Yan, Xiaoliang Wang
フォーマット:	論文
言語:	英語
出版事項:	BMC 2025-07-01
主題:	DNA methylation Decitabine Sorafenib OATP1B3 Hepatocellular carcinoma
オンライン･アクセス:	https://doi.org/10.1186/s13148-025-01925-w